Cargando…
Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study
BACKGROUND: Patients with diabetic cardiomyopathy have an impaired myocardial glucose handling and distal distribution of coronary atherosclerosis. Trimetazidine, an anti-ischemic metabolic agent, improves myocardial glucose utilization though inhibition of fatty acid oxidation. Aim of the present s...
Autores principales: | Rosano, Giuseppe MC, Vitale, Cristiana, Sposato, Barbara, Mercuro, Giuseppe, Fini, Massimo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC305354/ https://www.ncbi.nlm.nih.gov/pubmed/14641923 http://dx.doi.org/10.1186/1475-2840-2-16 |
Ejemplares similares
-
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005) -
Efficacy and Safety of Novel Aspirin Formulations: A Randomized, Double-Blind, Placebo-Controlled Study
por: Mollace, Rocco, et al.
Publicado: (2022) -
Trimetazidine offers myocardial protection in elderly coronary artery disease patients undergoing non-cardiac surgery: a randomized, double-blind, placebo-controlled trial
por: Dai, Zhong-Liang, et al.
Publicado: (2021) -
Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial
por: Wu, Lili, et al.
Publicado: (2020) -
Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine
por: Ferraro, Elisabetta, et al.
Publicado: (2016)